Search | Clinical Trials Finder

Conditions: Meibomian Gland Dysfunction, Dry Eye Disease
Interventions: Nordlys SWT IPL, Meibomian Gland Expression (MGX), Sham Nordlys SWT IPL; Device · Procedure
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Marlborough, Massachusetts

Conditions: Dry Eye Disease
Interventions: glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%; Drug
Lead sponsor: Calm Water Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye Disease (DED)
Interventions: OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray; Drug
Lead sponsor: Oyster Point Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more

Conditions: Dry Eye Disease
Interventions: rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution); Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more

Conditions: Dry Eye Disease (DED)
Interventions: Acoltremon; Drug
Lead sponsor: Colvard Kandavel Eye Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Encino, California

Conditions: Dry Eye Disease
Interventions: CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more

Conditions: Dry Eye Disease (DED)
Interventions: Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab; Other · Drug
Lead sponsor: Oculis; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 14
States / cities: Aliso Viejo, California • Garden Grove, California • Glendale, California + 11 more

Conditions: Dry Eye Disease (DED)
Interventions: 3% trehalose; Drug
Lead sponsor: Southern California College of Optometry at Marshall B. Ketchum University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Dry Eye
Interventions: AXR-159, Vehicle; Drug
Lead sponsor: AxeroVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee

Conditions: Dry Eye Syndrome (DES), Dry Eye Disease (DED)
Interventions: Miebo four times per day; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Bozeman, Montana • Omaha, Nebraska • Fargo, North Dakota + 1 more

Conditions: Dry Eye Disease (DED)
Interventions: Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%; Drug
Lead sponsor: Andover Research Eye Institute; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye Disease (DED)
Interventions: Active Comparator EBI-005, Placebo Comparator; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 45
States / cities: Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more

Conditions: Kerato Conjunctivitis Sicca
Interventions: KPI-121 Ophthalmic Suspension, Vehicle; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 81
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more

Conditions: Dry Eye Syndromes
Interventions: Cyclosporine A, Placebo; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more

Conditions: Dry Eye Disease
Interventions: AZR-MD-001, Vehicle; Drug · Other
Lead sponsor: Azura Ophthalmics; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Chandler, Arizona • Glendale, California • Newport Beach, California + 13 more

Conditions: Dry Eye
Interventions: EBI-005, Placebo; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more

Conditions: Dry Eye
Interventions: Miebo, Saline; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Glendale, California • Murrieta, California • Newport Beach, California + 9 more

Conditions: Dry Eye
Interventions: OTX-DED; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 15
States / cities: Inglewood, California • Mission Hills, California • Newport Beach, California + 12 more

Conditions: Dry Eye Disease
Interventions: OTX-CSI, Placebo Vehicle; Drug · Other
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more

Conditions: Dry Eye Disease
Interventions: OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray; Drug · Other
Lead sponsor: Vance Thompson Vision - MT; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Dry Eye Disease
Interventions: Lotemax, Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears), In Vivo Confocal Microscopy (IVCM); Drug · Diagnostic Test
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye Disease (DED)
Interventions: Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML; Device
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Dry Eye Disease (DED)
Interventions: DFL24498, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Chandler, Arizona • Azusa, California • Glendale, California + 21 more

Conditions: Dry Eye Disease (DED)
Interventions: acoltremon 0.003%; Drug
Lead sponsor: Center for Sight Las Vegas; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

Phase 3 Study of EBI-005 in Dry Eye Disease

Safety and Efficacy of KPI-121 in Subjects With DED

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Study of EBI-005 in Dry Eye Disease (DED)

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED

Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)